Clotblog with Dr Samuel Goldhaber

View all posts »

Focus on AF in Latin America with the GARFIELD registry

Jan 22, 2013 15:25 EST


The perspective from Mexico, Chile, Argentina, and Brazil on AF in the "real-life" setting—as opposed to the controlled environment of a clinical trial—is an important part of this ambitious study, which seeks to enroll 55 000 people worldwide. Find out more.

 

See also:

Kakkar AK, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012;163:13-19. Abstract








Your comments
Focus on AF in Latin America with the GARFIELD registry
# 1 of 1
January 25, 2013 12:11 (EST)
Leopoldo Piegas
TTR
Dear Sam,
Happy New Year!
In NOAC trials the TTR was lower in developing countries, even in Brazil, despite frequent INR controls and flow charts to be followed by investigators. The explanation is only based on socio-economic issues?
Kind regards
Leopoldo
Author's disclosure (Jan 25, 2013)
Re-Ly National Coordinator in Brazil

You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA